Clinical Trial Finder | Pancreatic Cancer Action Network

Back to Trial Search

Phase I/II Trial of GP-2250 in Combination With Gemcitabine in Pancreatic Adenocarcinoma After FOLFIRINOX Chemotherapy

Summary

The purpose of this phase I/II trial is to evaluate the safety and tolerability of GP-2250 in combination with gemcitabine in patients with pancreatic adenocarcinoma after FOLFIRINOX chemotherapy.

General Information

NCT#: NCT03854110
Study ID: GP-2250-1001
Trial Phase: Phase I/II

Trial Sponsor: Geistlich Pharma AG
Therapies Used in This Trial: Gemcitabine, GP-2250

Request a Healthcare Provider account to access Trial Eligibility and Site Information.

View Details

An authorized Healthcare Provider account is required to access Trial Eligibility and Site Information. Already have an account? Sign In

Request an Account

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account.
In order to view this information, you need to be signed in as a Health Care Provider.
In order to see the trial eligibility criteria, you need to be signed in as a Health Care Provider.
This information is restricted to validated Health Care Providers.

Eligibility

-------------------------------------------------------------------------------------------

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account by clicking on the Request button.
------------------------------------------------------------------------------------------------------
In order to view this information, you need to be signed in as a Health Care Provider. You are currently not authorized.

Site Information

Back to Trial Search